Therapeutic potential of peptide deformylase inhibitors against experimental tuberculosis

Journal of Infection

Volumn 60, Issue 6, 2010, Pages 498-501

  Sharma, Anshika ^a   Khuller, G K ^b   Kanwar, A J ^b   Sharma, Sadhna ^b  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINONIN; ISONIAZID; N (1 TERT BUTYL 2 DIMETHYLAMINO 2 OXOETHYL) 2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANAMIDE; PEPTIDE DEFORMYLASE INHIBITOR; PYRAZINAMIDE; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; BACTERIAL COUNT; BACTERIAL GROWTH; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG POTENCY; LETTER; LUNG HOMOGENATE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SPLEEN; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS;

AMIDOHYDROLASES; ANALYSIS OF VARIANCE; ANIMALS; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HYDROXAMIC ACIDS; ISONIAZID; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS;

EID: 77953323923     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.03.009     Document Type: Letter

References (13)

1. Wallis R.S., Patil S., Cheon S.H., Edmonds K., Phillips M., Perkins M.D., et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999, 43:2600-2606.
2. Goldman R.C., Plumley K.V., Laughon B.E. The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control. Infect Disord Drug Targets 2007, 7:73-91.
3. Giglione C., Pierre M., Meinnel T. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol 2000, 36:1197-1205.
4. Adams J.M., Capecchi M. N-formylmethionine-sRNA as the initiator of protein synthesis. Proc Natl Acad Sci U S A 1966, 55:147-155.
5. Nguyen K.T., Hu X., Colton C., Chakrabarti R., Zhu M.X., Pei D. Characterization of a human PDF: implications for antibacterial drug design. Biochemistry 2003, 42:9952-9958.
6. Clements J.M., Beckett R.P., Brown A., Catlin G., Lobell M., Palan S., et al. Antibiotic activity and characterization of BB-3497, a novel PDF inhibitor. Antimicrob Agents Chemother 2001, 45:563-570.
7. Chen D., Yuan Z. Therapeutic potential of peptide deformylase inhibitors. Expert Opin Investig Drugs 2005, 14:1107-1116.
8. Teo J.W., Thayalan P., Beer D., Yap A.S., Nanjundappa M., Ngew X., et al. PDF inhibitors as potent antimycobacterial agents. Antimicrob Agents Chemother 2006, 50:3665-3673.
9. v. Int J Antimicrob Agents 2009, 34:226-230.
10. Lee M.D., Antczak C., Li Y., et al. A new human PDF inhibitable by actinonin. Biochem Biophys Res Commun 2003, 312:309-315.
11. Ahmad Z., Pandey R., Sharma S., Khuller G.K. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int J Antimicrob Agents 2006, 27(5):409-416.
12. Cynamon M.H., Alvirez-Freites E., Yeo A.E. BB-3497, a PDF inhibitor, is active against Mycobacterium tuberculosis. J Antimicrob Chemother 2004, 53:403-405.
13. Ramanathan-Girish S., McColm J., Clements J.M., Taupin P., Barrowcliffe S., Hevizi J., et al. Pharmacokinetics in animals and humans of a first-in-class PDF inhibitor. Antimicrob Agents Chemother 2004, 48:4835-4842.